In a large monocentric observational study involving 262 patients with moderate-risk (n = 127) and high-risk (n = 135) germline RET mutations, Voss et al. reported that both moderate- and high-risk patients had similar overall survival (OS), metastatic disease after MTC diagnosis, and clinical outcomes, suggesting that moderate- and high-risk RET mutations do not predict MTC aggressiveness [42]. This evidence concerns the gene RET and metastatic neoplasm.